Mammography Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
RDNT | B | RadNet, Inc. | -0.87 | |
PHG | C | Koninklijke Philips N.V. | -0.42 | |
HOLX | D | Hologic, Inc. | 1.04 | |
ICAD | D | icad inc. | -3.56 |
Related Industries: Diagnostics & Research Medical Instruments & Supplies Software - Application
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
LGHT | D | Langar Global HealthTech ETF | 4.87 | |
EKG | B | First Trust Nasdaq Lux Digital Health Solutions ETF | 3.76 | |
PSCH | C | PowerShares S&P SmallCap Health Care Portfolio | 3.44 | |
MDCP | B | VictoryShares THB Mid Cap ESG ETF | 2.93 | |
RJMG | A | FT Raymond James Multicap Growth Equity ETF | 2.91 |
Compare ETFs
- Mammography
Mammography (also called mastography) is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications.
As with all X-rays, mammograms use doses of ionizing radiation to create images. These images are then analyzed for abnormal findings. It is usual to employ lower-energy X-rays, typically Mo (K-shell x-ray energies of 17.5 and 19.6 keV) and Rh (20.2 and 22.7 keV) than those used for radiography of bones. Ultrasound, ductography, positron emission mammography (PEM), and magnetic resonance imaging (MRI) are adjuncts to mammography. Ultrasound is typically used for further evaluation of masses found on mammography or palpable masses not seen on mammograms. Ductograms are still used in some institutions for evaluation of bloody nipple discharge when the mammogram is non-diagnostic. MRI can be useful for further evaluation of questionable findings, as well as for screening pre-surgical evaluation in patients with known breast cancer, in order to detect additional lesions that might change the surgical approach, for example, from breast-conserving lumpectomy to mastectomy. Other procedures being investigated include tomosynthesis.
For the average woman, the U.S. Preventive Services Task Force recommends (2016) mammography every two years between the ages of 50 and 74, concluding that "the benefit of screening mammography outweighs the harms by at least a moderate amount from age 50 to 74 years and is greatest for women in their 60s". The American College of Radiology and American Cancer Society recommend yearly screening mammography starting at age 40. The Canadian Task Force on Preventive Health Care (2012) and the European Cancer Observatory (2011) recommend mammography every 2 to 3 years between ages 50 and 69. These task force reports point out that in addition to unnecessary surgery and anxiety, the risks of more frequent mammograms include a small but significant increase in breast cancer induced by radiation. Additionally, mammograms should not be performed with increased frequency in patients undergoing breast surgery, including breast enlargement, mastopexy, and breast reduction. The Cochrane Collaboration (2013) concluded after ten years that trials with adequate randomization did not find an effect of mammography screening on total cancer mortality, including breast cancer. The authors of this Cochrane review write: "If we assume that screening reduces breast cancer mortality by 15% and that overdiagnosis and over-treatment is at 30%, it means that for every 2,000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings." The authors conclude that the time has come to re-assess whether universal mammography screening should be recommended for any age group. They state that universal screening may not be reasonable. The Nordic Cochrane Collection updated research in 2012 and stated that advances in diagnosis and treatment make mammography screening less effective today, rendering it “no longer effective.” They conclude that “it therefore no longer seems reasonable to attend” for breast cancer screening at any age, and warn of misleading information on the internet.Mammography has a false-negative (missed cancer) rate of at least ten percent. This is partly due to dense tissue obscuring the cancer and the appearance of cancer on mammograms having a large overlap with the appearance of normal tissue. A meta-analysis review of programs in countries with organized screening found a 52% over-diagnosis rate.
Popular Now
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Featured Articles